197 related articles for article (PubMed ID: 17948601)
1. PEG-IFN, RBV dosing during chronic HCV re-treatment.
Highleyman L
IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
[No Abstract] [Full Text] [Related]
2. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
3. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
4. [McHutchison's legacy and adherence in hepatitis C].
Ibarra Barrueta O
Farm Hosp; 2013; 37(5):424-5. PubMed ID: 24128108
[No Abstract] [Full Text] [Related]
5. [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
Xie Y; Li MH
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):484-6. PubMed ID: 19912677
[No Abstract] [Full Text] [Related]
6. ADVANCE study begins enrollment.
AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
[No Abstract] [Full Text] [Related]
7. [The study of optimal treatment in patients with refractory chronic hepatitis C].
Chen XY; Zhang YH
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
[No Abstract] [Full Text] [Related]
8. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
[No Abstract] [Full Text] [Related]
9. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
10. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
[TBL] [Abstract][Full Text] [Related]
11. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
12. [Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):486-7. PubMed ID: 19912678
[No Abstract] [Full Text] [Related]
13. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
van Leusen R; Adang RP; de Vries RA; Cnossen TT; Konings CJ; Schalm SW; Tan AC
Nephrol Dial Transplant; 2008 Feb; 23(2):721-5. PubMed ID: 18042614
[TBL] [Abstract][Full Text] [Related]
14. The treatment of viral hepatitis, present and future.
Rodés J
J Hepatobiliary Pancreat Surg; 2003; 10(2):163-7. PubMed ID: 14505150
[No Abstract] [Full Text] [Related]
15. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
16. Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?
Lutchman G; Ghany M
Hepatology; 2005 Feb; 41(2):234-6. PubMed ID: 15657958
[No Abstract] [Full Text] [Related]
17. [High dose repeat therapy in previously treated patients with chronic hepatitis C].
Hoepffner N; Paul KA; Nikodem AB; Teuber G
Dtsch Med Wochenschr; 2006 Mar; 131(11):543-4. PubMed ID: 16538557
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
19. [Treatment for chronic hepatitis C, more opportunity, more challenge].
Wei L
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
[No Abstract] [Full Text] [Related]
20. Customizing treatment to patient populations.
Brown RS
Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4 Suppl 1():S3-9. PubMed ID: 17235282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
